$6.89 Billion is the total value of Bellevue Group AG's 202 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -14,800 | -100.0% | 0.00% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -212 | -100.0% | -0.00% | – |
| DLB | Exit | DOLBY LABORATORIES INC | $0 | – | -1,600 | -100.0% | -0.00% | – |
| ACHC | Exit | ACADIA HEALTHCARE CO IN | $0 | – | -1,287 | -100.0% | -0.00% | – |
| MKTX | Exit | MARKETAXESS HLDGS INC | $0 | – | -662 | -100.0% | -0.00% | – |
| MELI | Exit | MERCADOLIBRE INC | $0 | – | -170 | -100.0% | -0.00% | – |
| BLU | Exit | BELLUS HEALTH INC | $0 | – | -44,905 | -100.0% | -0.01% | – |
| DSGN | Exit | DESIGN THERAPEUTICS INC | $0 | – | -34,881 | -100.0% | -0.01% | – |
| NVCR | Exit | NOVOCURE LTD | $0 | – | -9,000 | -100.0% | -0.01% | – |
| BLI | Exit | BERKELEY LTS INC | $0 | – | -385,014 | -100.0% | -0.01% | – |
| A | Exit | AGILENT TECHNOLOGIES INC | $0 | – | -7,978 | -100.0% | -0.02% | – |
| RCUS | Exit | ARCUS BIOSCIENCES INC | $0 | – | -65,864 | -100.0% | -0.02% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -12,411 | -100.0% | -0.02% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -1,622,522 | -100.0% | -0.03% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -1,290,278 | -100.0% | -0.07% | – |
| TFX | Exit | TELEFLEX INCORPORATED | $0 | – | -25,066 | -100.0% | -0.08% | – |
| AVTR | Exit | AVANTOR INC | $0 | – | -471,621 | -100.0% | -0.13% | – |
| ADPT | Exit | ADAPTIVE BIOTECHNOLOGIES COR | $0 | – | -2,960,131 | -100.0% | -0.30% | – |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -5,910,639 | -100.0% | -2.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.